Darboren^TM

Indication:
Treatment of anemia due to:
• Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis
• The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

Dosage & Administration:
Recommended starting dose for patients with CKD on dialysis
• 0.45 mcg/kg intravenously or subcutaneously weekly or
• 0.75 mcg/kg intravenously or subcutaneously every 2 weeks
• Intravenous route is recommended for patients on hemodialysis
Recommended starting dose for patients with CKD not on dialysis
• 0.45 mcg/kg intravenously or subcutaneously at 1 month interval
Recommended starting dose for pediatric patients with CKD
• 0.45 mcg/kg intravenously or subcutaneously weekly
• Patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks
Recommended starting dose for patients with cancer on chemotherapy
• 2.25 mcg/kg subcutaneously weekly, or
• 500 mcg subcutaneously every 3 weeks

Preparation:
Darboren^TM Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 25 mcg of Darbepoetin alfa in Alu-PVC blister pack.
Darboren^TM Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 40 mcg of Darbepoetin alfa in Alu-PVC blister pack.
Darboren^TM 60 Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 60 mcg of Darbepoetin alfa in Alu-PVC blister pack.